Ibogaine Research Database

692 research records indexed from PubMed. Plain-language summaries where available.

Of these, 52 are human clinical studies (trials, observational studies, or case reports), 398 are preclinical (animal or lab) studies, and 112 are reviews or meta-analyses summarizing other researchers’ data. A record appearing here does not by itself mean ibogaine is proven effective for a given condition — see each condition page’s evidence breakdown for what’s actually established.

Compare evidence by condition →

All Studies (692)Depression (56)PTSD (24)Alcohol Addiction (20)Heroin Addiction (16)Opioid Addiction (15)Cocaine Addiction (15)Anxiety (13)Methamphetamine Addiction (12)Traumatic Brain Injury (2)

Studies on Methamphetamine Addiction(12 of 692)

← Back to Methamphetamine Addiction

Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada.

Langlois, Fairbairn, Jutras-Aswad· Substance use & addiction journal· 2025· PMID: 39614597
Unclassified

It has been suggested that opioid agonist therapy (OAT) may have a secondary benefit of reducing methamphetamine/amphetamine use. However, current evidence is limited and conflicting, and little is known on the impacts of different OATs on methamphetamine/amphetamine use. The aim...

Marked Increase in Amphetamine-Related Emergency Department Visits and Inpatient Admissions in Toronto, Canada, 2014-2021.

Tardelli, Johnstone, Xu· Canadian journal of psychiatry. Revue canadienne de psychiatrie· 2023· PMID: 36809914
Unclassified

We report emergency department and inpatient amphetamine-related trends focusing on co-occurring substance use and psychiatric diagnoses at the Centre for Addiction and Mental Health, the largest mental health teaching hospital in Canada. We describe yearly trends in amphetamine-...

Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials.

Bakouni, Sharafi, Bahremand· Drug and alcohol dependence· 2023· PMID: 37979478
Meta-Analysis

This meta-analysis (PROSPERO-ID: CRD42022362962), pooled effect estimates of outcomes, from placebo-controlled randomized clinical trials (RCTs) examining bupropion efficacy and safety for amphetamine-type stimulant use disorder (ATSUD) treatment. Electronic databases were search...

Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration.

Glick, Sell, Maisonneuve· European journal of pharmacology· 2008· PMID: 18930043
Preclinical (Animal)

The novel iboga alkaloid congener 18-methoxycoronaridine (18-MC) is a putative anti-addictive agent that has been shown, in rats, to decrease the self-administration of several drugs of abuse. Previous work has established that 18-MC is a potent antagonist at alpha3beta4 nicotini...

Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration.

Glick, Maisonneuve, Kitchen· European journal of pharmacology· 2002· PMID: 11906717
Preclinical (Animal)

The iboga alkaloid ibogaine and the novel iboga alkaloid congener 18-methoxycoronaridine are putative anti-addictive agents. Using patch-clamp methodology, the actions of ibogaine and 18-methoxycoronaridine at various neurotransmitter receptor ion-channel subtypes were determined...

A review of chemical agents in the pharmacotherapy of addiction.

Levi, Borne· Current medicinal chemistry· 2002· PMID: 12369879
Review

Chemical substance abuse has tormented mankind throughout history. A number of chemical approaches have been employed in an attempt to treat chemical addiction. Unfortunately, most of these have proven unsuccessful though several chemical entities have been shown to be moderately...

Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation.

Onaivi, Ali, Chirwa· Annals of the New York Academy of Sciences· 2002· PMID: 12105083
Review

The mapping of the human genetic code will enable us to identify potential gene products involved in human addictions and diseases that have hereditary components. Thus, large-scale, parallel gene-expression studies, made possible by advances in microarray technologies, have show...

Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: Implications for their antiaddictive properties.

Szumlinski, Haskew, Balogun· Pharmacology, biochemistry, and behavior· 2001· PMID: 11509208
Preclinical (Animal)

This study investigated the effects of pretreatment with the putative antiaddictive compound, ibogaine (IBO), and its synthetic derivative, 18-methoxycoronaridine (18-MC), on the changes in behaviour in an elevated plus maze and the changes in corticosterone (CORT) produced by a ...

Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats.

Szumlinski, Balogun, Maisonneuve· Psychopharmacology· 2000· PMID: 10972470
Preclinical (Animal)

The phenomenon of sensitization has been theoretically implicated in mediating various aspects of drug addiction. Recent dose-response studies demonstrated that pretreatment with the putative antiaddictive agent, ibogaine (IBO), and a synthetic iboga alkaloid congener, 18-methoxy...

18-MC reduces methamphetamine and nicotine self-administration in rats.

Glick, Maisonneuve, Dickinson· Neuroreport· 2000· PMID: 10884062
Preclinical (Animal)

In previous studies, 18-methoxycoronaridine (18-MC), a novel iboga alkaloid congener, has been found to decrease the intravenous self-administration of morphine and cocaine in rats. In the present study, 18-MC (1-40 mg/kg, i.p.) dose-dependently decreased the i.v. self-administra...

Ibogaine blocked methamphetamine-induced hyperthermia and induction of heat shock protein in mice.

Yu, Imam, Newport· Brain research· 1999· PMID: 10095030
Preclinical (Animal)

Body temperature changes and heat shock protein (HSP-72) induction in the caudate nucleus were studied in female C57BL/6N mice pretreated with ibogaine (50 mg/kg) and sacrificed 48 h. after a single dose of methamphetamine (20 mg/kg). Methamphetamine injection resulted in hyperth...

Differential responses by neurotensin systems in extrapyramidal and limbic structures to ibogaine and cocaine.

Alburges, Hanson· Brain research· 1999· PMID: 9914442
Preclinical (Animal)

Ibogaine (Endabuse) is a psychoactive indole alkaloid found in the West African shrub, Tabernanthe iboga. This drug interrupts cocaine and amphetamine abuse and has been proposed for treatment of addiction to these stimulants. However, the mechanism of action that explains its ph...